Business Combination, Asset Acquisitions, and Disposition - (Tables)

12 Months Ended

Dec. 31, 2018

Summary of assets and liabilities assumed in acquisition

The fair values of assets acquired and liabilities assumed at the closing date of the Celator Acquisition are summarized below (in thousands):



Cash and cash equivalents	$	26,137
Other receivables	386
Prepaid expenses and deposits	151
Property, plant and equipment	767
Intangible assets	1,811,250
Goodwill	252,825
Other non-current assets	43
Accrued liabilities	(19,076		)
Deferred tax liability, net, non-current	(542,901		)
Other non-current liabilities	(1,002		)
Total acquisition consideration - cash paid	$	1,528,580

Summary of pro forma financial information

The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations and are as follows (in thousands, except per share data):



	Year Ended December 31, 2016
Revenues	$	1,488,118
Net income attributable to Jazz Pharmaceuticals plc	$	386,342
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - basic	$	6.39
Net income attributable to Jazz Pharmaceuticals plc per ordinary share - diluted	$	6.24